JNJ Dividend Dominance Over MRK

Johnson & Johnson (NYSE:JNJ) and Merck (NYSE:MRK), two pharmaceutical giants, are being compared to determine which one's dividend is stronger for retirement-focused income. Both stocks have seen significant gains in 2026, with Merck up 40.18% year-to-date and J&J at 29.1%. However, the question remains which payout will hold up through the next decade of patent expirations.

J&J's dividend history shows a raise every year from 2009 to 2026, climbing from $0.46 to $1.34 per quarter. Merck has also raised its dividend recently, but its record includes a flat stretch at $0.38 from 2010 into 2011. J&J produced $19.7 billion of free cash flow in 2025 and guides to a full-year figure approaching $21 billion, while Merck's management has not provided a payout ratio or free cash flow figure.

MERCK faces a patent cliff exposure with nearly half of its pharma revenue coming from Keytruda. The franchise grew just 4% to $8.4 billion last quarter as management noted moderating U.S. growth. Three Phase 3 oncology trials failed, and CEO Rob Davis calls the transition 'more of a hill than a cliff,' mentioning more than 20 new products and greater than $70 billion of commercial opportunity.

JNJ has already taken its hit on patent expiration, while Merck's still lies ahead. JNJ also has a longer raise record, disclosed cash coverage, and a patent cliff already in the rearview. Verdict: J&J owns the retirement income slot with its stronger dividend record and less exposure to patent expirations.